id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-D-5473-0029,FDA,FDA-2019-D-5473,"Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products Questions and Answers Guidance for Industry",Other,Guidance,2025-12-10T05:00:00Z,2025,12,2025-12-10T05:00:00Z,,2025-12-10T20:21:24Z,,1,0,09000064b90c20c5
FDA-2019-D-5473-0028,FDA,FDA-2019-D-5473,"Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers; Guidance for Industry; Availability",Notice,Notice of Availability,2025-12-10T05:00:00Z,2025,12,,,2025-12-10T20:21:09Z,2025-22427,0,0,09000064b90c159b